-
公开(公告)号：US20240050430A1
公开(公告)日：2024-02-15
申请号：US18213464
申请日：2023-06-23
Applicant: Amgen Inc.
Inventor： John Gordon ALLEN , Jennifer Rebecca ALLEN , Ana Elena MINATTI , Qiufen XUE , Ryan Paul WURZ , Christopher M. TEGLEY , Alexander J. PICKRELL , Thomas T. NGUYEN , Vu Van MA , Patricia LOPEZ , Longbin LIU , David John KOPECKY , Michael J. FROHN , Ning CHEN , Jian Jeffrey CHEN , Aaron C. SIEGMUND , Albert AMEGADZIE , Nuria A. TAMAYO , Shon BOOKER , Clifford GOODMAN , Mary WALTON , Nobuko NISHIMURA , Youngsook SHIN , Jonathan D. LOW , Victor J. CEE , Anthony B. REED , Hui-Ling WANG , Brian Alan LANMAN
IPC: A61K31/517 , A61P35/00 , A61K31/4985 , A61K39/395 , C07D403/04 , C07D471/04
CPC classification number: A61K31/517 , A61P35/00 , C07D471/04 , A61K39/39558 , C07D403/04 , A61K31/4985
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20220175782A1
公开(公告)日：2022-06-09
申请号：US17579359
申请日：2022-01-19
Applicant: AMGEN INC.
Inventor： John Gordon ALLEN , Brian Alan LANMAN , Jian CHEN , Anthony B. REED , Victor J. CEE , Longbin LIU , Patricia LOPEZ , Ryan Paul WURZ , Thomas T. NGUYEN , Shon BOOKER , Jennifer Rebecca ALLEN , Margaret CHU-MOYER , Albert AMEGADZIE , Ning CHEN , Clifford GOODMAN , Jonathan D. LOW , Vu Van MA , Ana Elena MINATTI , Nobuko NISHIMURA , Alexander J. PICKRELL , Hui-Ling WANG , Youngsook SHIN , Aaron C. SIEGMUND , Kevin C. YANG , Nuria A. TAMAYO , Mary WALTON , Qiufen XUE
IPC: A61K31/519 , A61K31/551 , A61K39/395 , A61P35/00
Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20220168280A1
公开(公告)日：2022-06-02
申请号：US17589163
申请日：2022-01-31
Applicant: AMGEN INC.
Inventor： Brian Alan LANMAN , Victor J. CEE , Alexander J. PICKRELL , Anthony B. REED , Kevin C. YANG , David John KOPECKY , Hui-Ling WANG , Patricia LOPEZ , Kate ASHTON , Shon BOOKER , Christopher M. TEGLEY
IPC: A61K31/428 , A61K31/496 , A61K31/519 , A61P35/00 , A61K31/5025 , A61K31/502 , A61K31/517 , C07D275/04 , C07D471/08 , C07D403/04 , C07D401/04 , C07D513/04 , C07D487/04 , C07D417/04 , C07D239/80 , C07D487/10 , C07D471/04
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20200171043A1
公开(公告)日：2020-06-04
申请号：US16783269
申请日：2020-02-06
Applicant: AMGEN INC.
Inventor： Paul E. HARRINGTON , Kate ASHTON , Sean P. BROWN , Matthew R. KALLER , Todd J. KOHN , Brian Alan LANMAN , Kexue LI , Yunxiao LI , Jonathan D. LOW , Ana Elena MINATTI , Alexander J. PICKRELL , Markian M. STEC , Joshua TAYGERLY
IPC: A61K31/553 , C07D498/08 , A61P35/00 , A61P35/02
Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
-
公开(公告)号：US20160176874A1
公开(公告)日：2016-06-23
申请号：US15058023
申请日：2016-03-01
Applicant: AMGEN INC.
Inventor： Jennifer R. ALLEN , Jian J. CHEN , Michael J. FROHN , Matthew R. KALLER , Qingyian LIU , Thomas T. NGUYEN , Alexander J. PICKRELL , Wenyuan QIAN , Robert M. RZASA , Wenge ZHONG
IPC: C07D471/04 , C07D403/14 , C07D401/14
CPC classification number: C07D471/04 , A61K31/497 , A61K31/517 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
-
Patent Agency Ranking
公开(公告)号：US20250057817A1
公开(公告)日：2025-02-20
申请号：US18443925
申请日：2024-02-16
Applicant: AMGEN INC.
Inventor： Brian Alan LANMAN , Victor J. CEE , Alexander J. PICKRELL , Anthony B. REED , Kevin C. YANG , David John KOPECKY , Hui-Ling WANG , Patricia LOPEZ , Kate ASHTON , Shon BOOKER , Christopher M. TEGLEY
IPC: A61K31/428 , A61K31/496 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61P35/00 , C07D239/80 , C07D275/04 , C07D401/04 , C07D403/04 , C07D417/04 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/10 , C07D513/04
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20190381064A1
公开(公告)日：2019-12-19
申请号：US16547747
申请日：2019-08-22
Applicant: AMGEN INC.
Inventor： Paul E. HARRINGTON , Kate ASHTON , Sean P. BROWN , Matthew R. KALLER , Todd J. KOHN , Brian Alan LANMAN , Kexue LI , Yunxiao LI , Jonathan D. LOW , Ana Elena MINATTI , Alexander J. PICKRELL , Markian M. STEC , Joshua TAYGERLY
IPC: A61K31/553 , A61P35/02 , A61P35/00 , C07D498/08
Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
-
8.发明申请公开(公告)号：US20170267673A1
公开(公告)日：2017-09-21
申请号：US15354877
申请日：2016-11-17
Applicant: AMGEN INC.
Inventor： Jennifer R. ALLEN , Albert AMEGADZIE , Matthew P. BOURBEAU , James A. BROWN , Jian J. CHEN , Yuan CHENG , Michael J. FROHN , Angel GUZMAN-PEREZ , Paul E. HARRINGTON , Longbin LIU , Qingyian LIU , Jonathan D. LOW , Vu Van MA , James R. MANNING , Ana Elena MINATTI , Thomas T. NGUYEN , Nobuko NISHIMURA , Mark H. NORMAN , Liping H. PETTUS , Alexander J. PICKRELL , Wenyuan QIAN , Shannon RUMFELT , Robert M. RZASA , Aaron C. SIEGMUND , Markian M. STEC , Ryan D. WHITE , Qiufen XUE
IPC: C07D417/12 , C07D417/14 , C07D471/04 , C07D279/08 , C07D417/04 , C07D513/10
CPC classification number: C07D417/12 , C07D279/08 , C07D417/04 , C07D417/14 , C07D471/04 , C07D513/10
Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
-
9.发明申请Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use 有权环丙基稠合噻嗪-2-胺化合物作为β-分泌酶抑制剂和使用方法公开(公告)号：US20160046618A1
公开(公告)日：2016-02-18
申请号：US14819256
申请日：2015-08-05
Applicant: AMGEN INC.
Inventor： Jennifer R. ALLEN , Albert AMEGADZIE , Matthew P. BOURBEAU , James A. BROWN , Jian J. CHEN , Yuan CHENG , Michael J. FROHN , Angel GUZMAN-PEREZ , Paul E. HARRINGTON , Longbin LIU , Qingyian LIU , Jonathan D. LOW , Vu Van MA , James MANNING , Ana Elena MINATTI , Thomas T. NGUYEN , Nobuko NISHIMURA , Mark H. NORMAN , Liping H. PETTUS , Alexander J. PICKRELL , Wenyuan QIAN , Shannon RUMFELT , Robert M. RZASA , Aaron C. SIEGMUND , Markian M. STEC , Ryan D. WHITE , Qiufen XUE
IPC: C07D417/12 , C07D471/04 , C07D513/10 , C07D417/14
CPC classification number: C07D417/12 , C07D279/08 , C07D417/04 , C07D417/14 , C07D471/04 , C07D513/10
Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
Abstract translation: 本发明提供了一类可用于调节β-分泌酶（BACE）活性的化合物。 所述化合物具有通式I：其中式I中的变量A4，A5，A6，A8以及R 1，R b，R 1，R 2，R 3和R 7各自独立地定义。 本发明还提供包含该化合物的药物组合物，以及该化合物和组合物用于治疗由BACE的生物学活性产生的与A-β斑块形成和沉积有关的病症和/或病症的用途。 这种BACE介导的疾病包括例如阿尔茨海默病，认知缺陷，认知障碍，精神分裂症和其他中枢神经系统疾病。 本发明还提供式II和III的化合物及其分子式实施方案，用于制备本发明化合物的中间体和方法。
-
10.发明申请公开(公告)号：US20150376221A1
公开(公告)日：2015-12-31
申请号：US14767737
申请日：2014-02-20
Applicant: AMGEN INC.
Inventor： John Gordon Allen , Christopher H. FOTSCH , Michael J. FROHN , John Douglas MCCARTER , Mirna MUJACIC , Alexander J. PICKRELL
CPC classification number: C07H7/02 , C07D309/10 , C07D309/14 , C07K16/2875 , C07K2317/14 , C07K2317/41 , C12N5/0603 , C12N2501/999 , C12N2510/00
Abstract: Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein.
Abstract translation: 式（I）的化合物可用作糖基化的调节剂。 式（I）的化合物具有以下结构：（I），本文提供其它变量的定义。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.072 seconds)
